MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH)*
Organization & Developments: Aurinia
Parents
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH)*
Children
*The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis
2016: Aurinia Pharma off 57% on high death rate in voclosporin study - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
2018: Aurinia Pharmaceuticals: Clear Winner In Lupus Nephritis_seekingalpha.com
2019: Aurinia eye drug falls short in improving tolerability versus Restasis, but beats on efficacy – Endpoints News
2019: Aurinia Pharmaceuticals: Update To Thesis And 2019 Outlook - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
2019: Comparative Analysis Reveals Voclosporin As A Drug With Mediocre Efficacy And Class-Typical Safety_seekingalpha.com
2019: Putting the safety issue to bed, Aurinia’s late-stage lupus nephritis data shines – Endpoints News
2020: Aurinia: A New Equilibrium_seekingalpha.com
2021: Assessing Aurinia Pharmaceuticals Post FDA Approva
2021: Aurinia Makes History as FDA Approves First Oral Drug for Lupus Nephritis
2021: Aurinia Pharmaceuticals In The Spotlight
2021: Aurinia Pharmaceuticals Is A Better Value Today At $17 Than It Was A Month Ago At $14
2021: Aurinia Should Be A Long-Term Winner With Lupkynis Now On The Market
2022: Aurinia: A Commercial Stage Company With Major Headwinds_ seekingalpha.com
2023: Aurinia Rides High On Lupkynis, But Not Without Cost (Rating Upgrade) (NASDAQ:AUPH)
2023: Aurinia: Despite Milder Shareholder Vote, A Bid To Sell Is Still Not Over
2024: Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
2024: Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates
2024: Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon
2024: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability
2024: Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
2024: Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment
2024: Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential
2024: Aurinia Pharmaceuticals: This Recovery Can Continue_seekingalpha.com
2024: Aurinia to stop drug trials, cut jobs after failing to find buyer; shares tank
2024: More turbulence at Aurinia as autoimmune drugmaker lays off 45% of workforce
2025: 3 Biotech Stocks With Notable Insider Buying
2025: Aurinia: My 2024 Sell Call Was Wrong - So I'm Upgrading To 'Hold' In 2025
2025: The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity
2026: Decoding Aurinia Pharmaceuticals Inc (AUPH): A Strategic SWOT Insight
Jumps
*Key People: Aurinia
Finance & Acquisition: Aurinia